Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BGB-45035 versus placebo in moderate to severe active rheumatoid arthritis
CTR20252981Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Sep 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BGB-45035 in rheumatoid arthritis (RA), sponsored by BeiGene. Started Sep 2025; status: terminated.
02
Drugs
BGB-45035
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20252981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252981.